Updated employee announcements, business news, awards, and recognition in the industry today.
People News
Synteract, a CRO providing full-service, Phase I-IV services, has added Cheryl Murphy as Senior Vice President, Clinical Development to its executive team.
Syntactx, a CRO that specializes in medical device, pharmaceutical and genetics clinical trials, announced the appointments of Marlene Barton to the position of Vice President, Department Head, Regulatory Affairs; Chie Iwaishi to the position of Senior Director, Regulatory Affairs; and Darlene Garner to the position of Manager, Regulatory Affairs.
Jane Byram
SCORR Marketing, a full-service marketing and communications firm, has announced the appointment of Jane Byram as media relations director.
Exostar, a provider of cloud-based solutions, announced it has hired Michael Castle to serve as Vice President of Sales and Marketing.
Maxime Stevens
Optimapharm, a full-service CRO, announced that Maxime Stevens is joining their team as Senior Vice President, Business Development.
Business News
Optimapharm, a full-service CRO, is expanding its office network by opening offices in Cambridge, UK.
Recognition
Certara, a company specializing in model-informed drug development, regulatory science, market access and real-world evidence services, announced that Clinical Pharmacology & Therapeutics has published its “Letter to the Editor” together with the EMA’s response. Certara also reported that 95% of novel new drug approvals by the US FDA in the first half of 2018 were supported by their software or services.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.